Name (Synonyms) | Correlation | |
---|---|---|
drug1163 | Ibrutinib Wiki | 0.71 |
drug332 | Best Practice Wiki | 0.58 |
Name (Synonyms) | Correlation | |
---|---|---|
D000741 | Anemia, Aplastic NIH | 1.00 |
D010265 | Paraproteinemias NIH | 1.00 |
D008998 | Monoclonal Gammopathy of Undetermined Significance NIH | 1.00 |
D008218 | Lymphocytosis NIH | 1.00 |
D009190 | Myelodysplastic Syndromes NIH | 0.58 |
D009369 | Neoplasms, NIH | 0.22 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100827 | Lymphocytosis HPO | 1.00 |
HP:0012133 | Erythroid hypoplasia HPO | 1.00 |
HP:0002863 | Myelodysplasia HPO | 0.58 |
HP:0002664 | Neoplasm HPO | 0.22 |
There is one clinical trial.
Severe acute respiratory syndrome (SARS) SARS-Cov-2 disease (COVID-19) is an infectious disease caused by a coronavirus. The pandemic first described in Wuhan, China, has since spread across the whole world and caused dramatic strain on health care in many countries. Patients infected with the virus mostly report mild to moderate respiratory symptoms like shortness of breath and coughing, and febrile symptoms. It is of paramount importance to preserve health service capacity by identifying those with serious illness without transferring all infected patients to emergency rooms or Hospitals. In addition, it is important to identify seriously ill patients early enough and before they reach a point of deterioration where they can be extremely challenging to handle in both prehospital and hospital environment. The present study is designed to sample biosensor data from patients treated and observed at home due to mild and moderate SARS-Cov-2 disease. Such a system would be useful, both for the treatment of individual patients as well as for assessing the efficacy and safety of care given to these patients. Investigators intend to improve quality and safety of home care by continuous monitoring and a set of rules for follow-up. Investigators hypothesized that patients and local health system may benefit from the feedback of a simple monitoring system, which detects changes in respiration, temperature and circulation variables in combination with the patient's subjective experiences of care. Patients may be referred to hospitalization earlier. In the present study we will use live continuous and non-continuous biosensor data to monitor the development of vital parameters for Covid 19 patients compared with patients who are not monitored electronically (standard of care).
Description: Day during home isolation it was stopped due to hospitalization
Measure: Stop home isolation Time: 1 to 21 daysDescription: 5 or >3 for one organ system
Measure: NEWS score Time: 1 to 21 daysDescription: Relevant vital clinical findings
Measure: Clinic at hospitalization Time: At admittance hospitalDescription: Symptoms developed during home isolation
Measure: Symptoms developed Time: Duration of home isolationDescription: Their description of vital sign development
Measure: Relative/peers evaluation of the patient Time: Duration of home isolationDescription: Referred to ICU, intubated, length of stay
Measure: Serious of symptoms at admittance hospital Time: Hospital stay